CoChat

Evolution of low HER2 expression between early and advanced-stage breast cancer

Tarantino, Paolo, Gandini, Sara, Nicolò, Eleonora, Trillo, Pamela, Giugliano, Federica, Zagami, Paola, Vivanet, Grazia, Bellerba, Federica, Trapani, Dario, Marra, Antonio, Esposito, Angela, Criscitiello, Carmen, Viale, Giuseppe, Curigliano, Giuseppe · 2022 · European Journal of Cancer
Cited by 187

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND Low human epidermal growth factor receptor 2 (HER2) expression is emerging as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 drugs. However, the evolution of this biomarker during the course of disease is still poorly characterised, and controversial data exist on its prognostic implications. METHODS We reviewed data of patients with HER2-negative BC according to the latest ASCO/CAP guidelines referred between January 2014 and December 2020. We grouped patients based on the immunohistochemistry (IHC) expression of HER2, HER2-zero (IHC 0) and HER2-low subgroup (IHC 1+ or 2+/ISH-negative) and evaluated the evolution of HER2 expression between the primary tumour and the first biopsy collected in the advanced setting. Disease-free survival, overall survival and progression-free survival were compared between patients with HER2-zero and HER2-low expression on the primary tumour. RESULTS 232 patients were included in the analysis. Among the overall population, there was a relevant discordance in HER2 expression between the primary tumour and the matched biopsy (K = 0.33, 95%CI 0.21-0.44): 44% of the HER2-zero primary tumour showed an increased HER2 score on biopsy, and 22% of the HER2-low primary tumours turned into HER2-IHC 0. The findings in the sub-populations of hormone-receptors positive (K = 0.32, 95%CI 0.19-0.45) and triple-negative tumours (K = 0.18, 95%CI -0.09-0.46) were consistent with the primary analysis. No difference in survival outcomes was observed between HER2-low and HER2-zero primary tumours. CONCLUSIONS HER2-low expression is dynamic in BC and may be enriched in the advanced-stage setting. No prognostic significance was demonstrated for HER2-low expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2021.12.022

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 187

Metadata

Authors
Tarantino, P., Gandini, S., Nicolò, E., Trillo, P., Giugliano, F., Zagami, P., Vivanet, G., Bellerba, F., Trapani, D., Marra, A., Esposito, A., Criscitiello, C., Viale, G., & Curigliano, G.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2022-03
Volume
163
Pages
35-43
ISSN
0959-8049 (ISSN-L)
OpenAlex
W4205795557
Cited by
187
References
3
FWCI
15.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evolution of low HER2 expression between early and advanced-stage breast cancer. https://app.cochat.ai/papers/10.1016/j.ejca.2021.12.022
The paper
Tarantino, P., Gandini, S., Nicolò, E., Trillo, P., Giugliano, F., Zagami, P., Vivanet, G., Bellerba, F., Trapani, D., Marra, A., Esposito, A., Criscitiello, C., Viale, G., & Curigliano, G. (2022). Evolution of low HER2 expression between early and advanced-stage breast cancer. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2021.12.022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.